Skip to content
Screener

LivaNova LIVN Q3 2025 earnings

Reported November 5, 2025 · Before market open

Revenue$357.8MBeat by $15.1M
EPS$1.11Beat by $0.19
Revenue estimate$342.7M
EPS estimate$0.92

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$381.1M
EPS estimate$1.04

Financials

Q3 2025

Income statement

See full
Revenue$357.8M+12.5%
Gross profit$244.9M+10.8%
Operating income$54.0M+51.6%
Net income$26.8M-18.7%
EPS (diluted)$0.49-18.3%

Balance sheet

See full
Cash & equivalents$646.1M-3.1%
Total debt$486.5M-28.4%
Total equity$1.2B-11.7%
Total assets$2.6B+1.4%

Cash flow

See full
Operating cash flow$85.1M+66.8%
CapEx$22.9M+26.1%
Free cash flow$62.2M+89.3%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.86B+0.4%
Enterprise value$2.7B-5.7%
P/S2.1×-0.2×

Profitability

See full
Gross margin67.8%+2.2pp
Operating margin14.4%+14.0pp
Net margin-16.1%-18.0pp
FCF margin14.2%+5.4pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.4×-0.1×
Current ratio1.3×-2.0×

Segments

By segment

See full
Cardiopulmonary$203.2M+18.0%
Neuromodulation$149.5M+6.9%

By geography

See full
Rest of World$99.6M+16.5%
Europe$67.7M+28.2%

FAQ

When did LivaNova report Q3 2025 earnings?
LivaNova (LIVN) reported Q3 2025 earnings on November 5, 2025 before market open.
What were LivaNova's Q3 2025 revenue and EPS?
LivaNova reported revenue of $357.8M and eps of $1.11 for Q3 2025.
Did LivaNova beat estimates in Q3 2025?
Revenue beat the consensus estimate of $342.7M by $15.1M. EPS beat the consensus estimate of $0.92 by $0.19.
How did LivaNova's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12.5% from $318.1M a year earlier and eps grew 23.3% from $0.90.
Where can I find LivaNova's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001639691-25-000146) and the 10-Q periodic report (0001639691-25-000150) directly on SEC EDGAR. The filing index links above go to sec.gov.